Kymora Scotland, MD, PHD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Endourology/Stone Disease)
    Ineligible company: 
    Boston Scientific
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    11/01/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Endourology/Stone Disease)
    Ineligible company: 
    Cook
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    11/01/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Endourology/Stone Disease)
    Ineligible company: 
    Karl Storz
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    11/01/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Endourology/Stone Disease)
    Ineligible company: 
    Ambu
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    11/01/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Endourology/Stone Disease)
    Ineligible company: 
    Advanced Medtech
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    11/01/2023
Return to Update Series (2023) Lesson 34: Stone Disease in Patients With Urinary Diversions: Pathophysiology, Workup, and Clinical Approach